ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA.
Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to potentially get FDA clearance for its platform that harvests live circulating tumor cells (CTCs) from a patient's blood.